Status:
COMPLETED
NexGen TM Tibia Clinical Outcomes Study
Lead Sponsor:
Zimmer Biomet
Conditions:
Osteoarthritis
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The objective of this study is to evaluate clinical performance for the commercially available NexGen TM Monoblock Tibia and NexGen TM Modular Tibia used in primary cementless tibia total knee arthrop...
Detailed Description
This is a prospective, multicenter, non-randomized clinical study designed to facilitate the collection and evaluation of radiographic parameters, pain and function, survival of the device, and advers...
Eligibility Criteria
Inclusion
- Patient is at least 18 years of age.
- Patient qualifies for a primary cementless tibia total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following:
- Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis.
- Collagen disorders and/or avascular necrosis of the femoral condyle.
- Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy.
- Moderate valgus, varus, or flexion deformities.
- The salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee.
- Patient has participated in the study-related Informed Consent process.
- Patient is willing and able to provide written Informed Consent by signing and dating the IRB approved Informed Consent Form.
- Patient is willing and able to complete scheduled study procedures and follow-up evaluations as described in the Informed Consent Form.
- Independent of study participation, patient is a candidate for commercially available cementless NexGen TM tibial knee component, implanted in accordance with product labeling.
Exclusion
- Previous history of infection in the affected joint.
- Active local or systemic infection that may affect the prosthetic joint.
- Insufficient bone stock on femoral or tibial surfaces.
- Skeletal immaturity.
- Neuropathic arthropathy.
- Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb.
- A stable, painless arthrodesis in a satisfactory functional position.
- Severe instability secondary to the absence of collateral ligament integrity.
- Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin.
- Patient has previously received partial or total knee arthroplasty for the ipsilateral knee.
- Patient is currently participating in any other surgical intervention studies or pain management studies.
- Patient is known to be pregnant or considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.).
- Patient has a known or suspected sensitivity or allergy to one or more of the implant materials.
Key Trial Info
Start Date :
October 3 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2023
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT03272373
Start Date
October 3 2017
End Date
March 31 2023
Last Update
December 30 2024
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
LA BioMed at Harbor-UCLA Medical Center
Torrance, California, United States, 90502
2
Cornerstone Orthopaedics & Sports Medicine, P.C.
Wheat Ridge, Colorado, United States, 80033
3
Franciscan Health
Mooresville, Indiana, United States, 46158
4
Henry County Orthopedics and Sports Medicine
New Castle, Indiana, United States, 47362